Chemotherapy and Standard Treatment Options
In a rare aggressive malignancy, any positive movement, no matter how small, is reported upon in “glowing terms.” In other malignancies, this chapter could stretch to the size of an entire book, but unfortunately, in malignant mesothelioma, to date, there is only one FDA-approved treatment and no approved second-line treatment. Providing a weighty chapter is impossible in a disease, which historically has had little in the way of developments since the approval of pemetrexed and cisplatin.
During my time as an oncology nurse and executive director of the Mesothelioma Applied Research Foundation, I have been a part of and offered my clinical expertise on more two dozen clinical trials using various chemotherapeutic combinations. This chapter will draw from my expertise as a nurse and while providing a historical context and practical tools for caring for mesothelioma patients during chemotherapy.
- Cinausero M, Rihawi K, Sperandi F, Melotti B, Ardizzoni A. Chemotherapy treatment in malignant pleural mesothelioma: a difficult history. J Thorac Dis. 2018;10(Suppl 2):S304–10. https://doi.org/10.21037/jtd.2017.10.19. Review. PubMed PMID: 29507800; PubMed Central PMCID: PMC5830568.CrossRefPubMedPubMedCentralGoogle Scholar
- Tomek S, Emri S, Krejcy K, Manegold C. Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Br J Cancer. 2003;88(2):167–74. http://doi.org.ezproxy.cul.columbia.edu/10.1038/sj.bjc.6600673 CrossRefGoogle Scholar
- U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. A to Z list of cancer drug National Cancer Institute. 2018. Retrieved August 16, 2018, from https://www.cancer.gov/about-cancer/treatment/drugs